RecruitingNCT07450612
Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection
Studying Constitutional mismatch repair deficiency syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- San Raffaele University
- Principal Investigator
- Giulia Martina Cavestro, MD, PhDIRCCS San Raffaele Hospital
- Intervention
- BEACON(diagnostic_test)
- Enrollment
- 1200 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2031
Study locations (4)
- Gastronterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Hospital, Milan, Lombardy, Italy
- Prof Giulia Martina Cavestro, MD PhD, Milan, Lombardy, Italy
- San Raffaele Scientific Institute, Gastroenterology and Gastrointestinal Endoscopy Unit, Milan, Lombardy, Italy
- Dipartimento di Chirurgia Oncologica e Dipartimento di Oncologia Sperimentale Istituto Nazionale Tumori, Milan, MI, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07450612 on ClinicalTrials.govOther trials for Constitutional mismatch repair deficiency syndrome
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT07523763Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal CancerBlokhin's Russian Cancer Research Center
- RECRUITINGNANCT06215677Neoadjuvant Immunotherapy for T4 dMMR Colon CancerPeking Union Medical College Hospital
- RECRUITINGPHASE2NCT05729646Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaYu jiren
- ACTIVE NOT RECRUITINGPHASE2NCT02983578Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT02359565Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or MedulloblastomaNational Cancer Institute (NCI)
See all trials for Constitutional mismatch repair deficiency syndrome →